MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) Fundamental Analysis & Valuation

BIT:1MDGL • US5588681057

Current stock price

412.7 EUR
+33.3 (+8.78%)
Last:

This 1MDGL.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. 1MDGL.MI Profitability Analysis

1.1 Basic Checks

  • In the past year 1MDGL has reported negative net income.
  • 1MDGL had a negative operating cash flow in the past year.
  • In the past 5 years 1MDGL always reported negative net income.
  • In the past 5 years 1MDGL always reported negative operating cash flow.
1MDGL.MI Yearly Net Income VS EBIT VS OCF VS FCF1MDGL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

  • The Return On Assets of 1MDGL (-21.22%) is comparable to the rest of the industry.
  • With a decent Return On Equity value of -46.21%, 1MDGL is doing good in the industry, outperforming 60.49% of the companies in the same industry.
Industry RankSector Rank
ROA -21.22%
ROE -46.21%
ROIC N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
1MDGL.MI Yearly ROA, ROE, ROIC1MDGL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • 1MDGL's Gross Margin of 95.25% is amongst the best of the industry. 1MDGL outperforms 92.59% of its industry peers.
  • 1MDGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
1MDGL.MI Yearly Profit, Operating, Gross Margins1MDGL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. 1MDGL.MI Health Analysis

2.1 Basic Checks

  • 1MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for 1MDGL has been increased compared to 1 year ago.
  • 1MDGL has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, 1MDGL has an improved debt to assets ratio.
1MDGL.MI Yearly Shares Outstanding1MDGL.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
1MDGL.MI Yearly Total Debt VS Total Assets1MDGL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 7.61 indicates that 1MDGL is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of 1MDGL (7.61) is better than 82.72% of its industry peers.
  • 1MDGL has a Debt/Equity ratio of 0.54. This is a neutral value indicating 1MDGL is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.54, 1MDGL perfoms like the industry average, outperforming 51.85% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Altman-Z 7.61
ROIC/WACCN/A
WACC12.22%
1MDGL.MI Yearly LT Debt VS Equity VS FCF1MDGL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • A Current Ratio of 3.44 indicates that 1MDGL has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 3.44, 1MDGL is doing good in the industry, outperforming 67.90% of the companies in the same industry.
  • 1MDGL has a Quick Ratio of 3.26. This indicates that 1MDGL is financially healthy and has no problem in meeting its short term obligations.
  • 1MDGL's Quick ratio of 3.26 is fine compared to the rest of the industry. 1MDGL outperforms 70.37% of its industry peers.
Industry RankSector Rank
Current Ratio 3.44
Quick Ratio 3.26
1MDGL.MI Yearly Current Assets VS Current Liabilites1MDGL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. 1MDGL.MI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 48.60% over the past year.
  • 1MDGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 864.21%.
EPS 1Y (TTM)48.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.81%
Revenue 1Y (TTM)864.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%362.03%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.70% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, 1MDGL will show a very strong growth in Revenue. The Revenue will grow by 86.68% on average per year.
EPS Next Y50.49%
EPS Next 2Y43.09%
EPS Next 3Y41.07%
EPS Next 5Y35.7%
Revenue Next Year443.67%
Revenue Next 2Y189.72%
Revenue Next 3Y130.48%
Revenue Next 5Y86.68%

3.3 Evolution

1MDGL.MI Yearly Revenue VS Estimates1MDGL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
1MDGL.MI Yearly EPS VS Estimates1MDGL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 50 100 150

More info and screens

Find the best growth stocksShow best growing peers

1

4. 1MDGL.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 1MDGL. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 465.28, 1MDGL can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, 1MDGL is valued a bit cheaper than the industry average as 69.14% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of 1MDGL to the average of the S&P500 Index (23.68), we can say 1MDGL is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 465.28
1MDGL.MI Price Earnings VS Forward Price Earnings1MDGL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300 400

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1MDGL.MI Per share data1MDGL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1MDGL does not grow enough to justify the current Price/Earnings ratio.
  • 1MDGL's earnings are expected to grow with 41.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.09%
EPS Next 3Y41.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1MDGL.MI Dividend Analysis

5.1 Amount

  • No dividends for 1MDGL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1MDGL.MI Fundamentals: All Metrics, Ratios and Statistics

MADRIGAL PHARMACEUTICALS INC

BIT:1MDGL (2/2/2026, 7:00:00 PM)

412.7

+33.3 (+8.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-19
Inst Owners96.8%
Inst Owner ChangeN/A
Ins Owners1.13%
Ins Owner ChangeN/A
Market Cap9.37B
Revenue(TTM)740.64M
Net Income(TTM)-289.13M
Analysts81.67
Price Target557.23 (35.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-42.41%
Min EPS beat(2)-133.61%
Max EPS beat(2)48.79%
EPS beat(4)3
Avg EPS beat(4)-8.49%
Min EPS beat(4)-133.61%
Max EPS beat(4)48.79%
EPS beat(8)5
Avg EPS beat(8)-2.09%
EPS beat(12)6
Avg EPS beat(12)-1.21%
EPS beat(16)8
Avg EPS beat(16)-1.44%
Revenue beat(2)2
Avg Revenue beat(2)21.21%
Min Revenue beat(2)13.88%
Max Revenue beat(2)28.53%
Revenue beat(4)4
Avg Revenue beat(4)15.85%
Min Revenue beat(4)2.78%
Max Revenue beat(4)28.53%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25.56%
PT rev (3m)25.56%
EPS NQ rev (1m)29.53%
EPS NQ rev (3m)29.53%
EPS NY rev (1m)-14.43%
EPS NY rev (3m)-14.43%
Revenue NQ rev (1m)0.27%
Revenue NQ rev (3m)0.27%
Revenue NY rev (1m)8%
Revenue NY rev (3m)8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 465.28
P/S 15.01
P/FCF N/A
P/OCF N/A
P/B 17.77
P/tB 17.98
EV/EBITDA N/A
EPS(TTM)-10.87
EYN/A
EPS(NY)0.89
Fwd EY0.21%
FCF(TTM)-6.11
FCFYN/A
OCF(TTM)-5.96
OCFYN/A
SpS27.49
BVpS23.23
TBVpS22.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.22%
ROE -46.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.25%
FCFM N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 274.34%
Cap/Sales 0.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.44
Quick Ratio 3.26
Altman-Z 7.61
F-Score4
WACC12.22%
ROIC/WACCN/A
Cap/Depr(3y)305.68%
Cap/Depr(5y)207.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.81%
EPS Next Y50.49%
EPS Next 2Y43.09%
EPS Next 3Y41.07%
EPS Next 5Y35.7%
Revenue 1Y (TTM)864.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%362.03%
Revenue Next Year443.67%
Revenue Next 2Y189.72%
Revenue Next 3Y130.48%
Revenue Next 5Y86.68%
EBIT growth 1Y43.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.01%
EBIT Next 3Y41.27%
EBIT Next 5YN/A
FCF growth 1Y45.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.97%
OCF growth 3YN/A
OCF growth 5YN/A

MADRIGAL PHARMACEUTICALS INC / 1MDGL.MI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) stock?

ChartMill assigns a fundamental rating of 3 / 10 to 1MDGL.MI.


Can you provide the valuation status for MADRIGAL PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to MADRIGAL PHARMACEUTICALS INC (1MDGL.MI). This can be considered as Overvalued.


How profitable is MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) stock?

MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) has a profitability rating of 2 / 10.


How financially healthy is MADRIGAL PHARMACEUTICALS INC?

The financial health rating of MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) is 6 / 10.